A carregar...
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
It has been over three decades since the hepatocyte growth factor (HGF) ligand and its receptor MET proto-oncogene (MET) pathway was established as promoting cancer growth and metastasis. MET exon 14 skipping (METex14) alterations occur in 3–4% of all non-small cell lung cancer (NSCLC) patients, typ...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7890719/ https://ncbi.nlm.nih.gov/pubmed/33643443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835921992976 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|